Jason Maguire

Jason Maguire, MD, MPH, joined the Sabin Vaccine Institute as its Vice President of Clinical Research & Development in January 2026.

An experienced infectious disease physician and clinical research scientist, in this role Jason collaborates with leadership team members, cross-functional leaders, and external partners to advance Sabin’s investigational vaccines through clinical development towards licensure and marketing authorization.
He has a strong track record in advancing investigational product clinical research from proof-of-concept through licensure and conducting clinical trials to inform public health policy in the US, Europe, and low-income countries in the tropics.

In his previous role as executive director for Clinical R&D for Hookipa Pharma, he advanced their arenavirus-vectored HIV treatment vaccine program though Phase 1, which led to purchase of the asset by Gilead.

Prior to his tenure at Hookipa Pharma, Jason served as the adolescent and adult meningococcal vaccine global clinical lead at Pfizer, leading multiple clinical trials supporting label change for their meningococcal B vaccine, advancing their pentavalent meningococcal vaccine from proof-of-concept through Phase 3 and licensure by the U.S. FDA, and preparing the submission for authorization by the European Medicines Agency.

Jason spent 25 years in the U.S. Navy as an infectious disease clinician and leader, driving force protection clinical research and development focusing on tropical and travel medicine infectious disease risks. He has significant experience developing clinical and basic science research capabilities in rural, underserved areas and low-income countries, including antimalarial drug resistance, molecular diagnostics, infectious disease epidemiology, outbreak investigation and response, and humanitarian assistance activities.

Jason earned his B.S. in molecular biology at Vanderbilt University, and his MD and MPH at the Uniformed Services University of the Health Sciences. He completed his Internal Medicine residency and Infectious Diseases fellowship at National Naval Medical Center (Walter Reed National Military Medical Center).
He is the author of more than 70 publications and book chapters.

A selection of his published works include:  

Wagner L, Obersriebnig M, Hochreiter R, Kadlecek V, Larcher-Senn J, Hegele L, Maguire JD, Murphy T, Derhaschnig U, Bézay N, Jaramillo JC, Eder-Lingelbach S, Messier M. Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2025 Nov 7:S1473-3099(25)00541-9. doi: 10.1016/S1473-3099(25)00541-9. Epub ahead of print. PMID: 41213278.

Peterson J, Drazan D, Czajka H, Maguire JD, Pregaldien JL, Seppa I, Maansson R, O’Neill R, Balmer P, Jodar L, Jansen KU, Anderson AS, Perez JL, Beeslaar J. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial. Lancet Infect Dis. 2023 Dec;23(12):1370-1382. doi: 10.1016/S1473-3099(23)00191-3. Epub 2023 Aug 11. PMID: 37579773.

Baird KJ, Maguire JD, Price RN. Diagnosis and treatment of Plasmodium vivax malaria. Adv Parasitol. 2012;80:203-70. doi: 10.1016/B978-0-12-397900-1.00004-9. PMID: 23199489.

Maguire JD, Sumawinata IW, Masbar S, Laksana B, Prodjodipuro P, Susanti I, Sismadi P, Mahmud N, Bangs MJ, Baird JK. Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia. Lancet. 2002 Jul 6;360(9326):58-60. doi: 10.1016/S0140-6736(02)09336-4. PMID: 12114045.

Maguire JD, Susanti AI, Krisin, Sismadi P, Fryauff DJ, Baird JK. The T76 mutation in the pfcrt gene of Plasmodium falciparum and clinical chloroquine resistance phenotypes in Papua, Indonesia. Ann Trop Med Parasitol. 2001 Sep;95(6):559-72. doi: 10.1080/00034980120092516. PMID: 11672462.

Return to Our People